




DRAFT
PDAB Data Project Presentation
July 31, 2026

Drug Cost Review, Affordability Determination, & UPL Cycle



Use of Selection Criteria/Ranking Elements

Number of NDCs on Candidate List

Option A	Option B	Option C
Candidate List of 30-60 NDCs based on applying Selection Criteria to the Master list and selecting the top 5-10 drugs from each of the six Selection Criteria. PRO – Necessary data can be gathered to populate list on timely and costs effective basis. CON – Significantly limits Board's choices of drugs for potential review.	Candidate List is the Master list of 10,000+ NDCs which includes data from the six Ranking Elements. PRO – Provides maximum flexibility for Board members to choose drugs they feel are important to review. CON – Acquiring the necessary data to populate the list would be time intensive and prohibitively expensive.	Candidate List for first round of reviews is a subset of the Master List (62.J drug list, the Maximum Fair Price drug list, and drugs recommended by Minnesota patient.) List of approximately 1300 NDCs that includes data from the six Ranking Elements. Board Members can add additional drugs. NEXT SLIDE

Option C

- Candidate drug list is comprised of the lists the legislature directed the PDAB to review (62.J.90 Criteria and patient identified drugs.)
- Leverages work done by CMS to establish Maximum Fair Price Drugs.
- Still provides broad drug list (1,300 + NDCs) for the Board to select for review.
- Still incorporates former Selection Criteria in the form of Ranking Elements to aid the Board's review and decision making.
- Necessary data can be obtained in a timely and affordable fashion.
- Does not prevent the PDAB from reviewing drugs from other lists in future drug review cycles (e.g. Drugs of Substantial Public Interest.)

Draft Selection Criteria/Ranking Elements for Candidate Drug List

DRAFT SELECTION CRITERIA/RANKING ELEMENTS

Total Annual Spend

Annual Utilization

Cost Per Day of Treatment

Cost Per Course of Treatment

Patient Out-of-Pocket Cost

Annual Percent Increase

OTHER CONSIDERATIONS

Minnesota Patient-Identified Drugs

Drug Product Characteristics

Timeline for 2026-2027 Drug Cost Reviews

July 31	Aug	Sept	Oct	Nov	Dec	Jan '27
Board Approves Ranking Elements And Candidate Drug List	Candidate Drug List Is Populated With Data And Ranking Elements	Board Reviews Candidate Drug List With Data And Ranking Elements	Board Selects Drugs For Review From Candidate Drug List	Conduct Reviews For Selected Drugs	Conduct Reviews For Selected Drugs	Conduct Reviews For Selected Drugs

NEXT STEPS FOR 2026

- **July 31 – Board reviews public comments and approves Ranking Elements and Candidate Drug List**
- **August – Populate Candidate Drug List with data and Ranking Elements**
- **September – Present Candidate Drug List with data and Ranking Elements for Board review and public comment**
- **October – Board reviews public comments and selects drugs for review from Candidate Drug List**
- **November and December – Ongoing Drug Cost Reviews**